ClinicalTrials.gg
Not yet recruitingNCT07337005REDEFINE-CMDUpdated Jan 13, 2026

CompREhensive Diagnostic Assessment of Coronary Endothelial Function Impairment and Vasospasm With CoNtinuous ThErmodilution in Patients With Suspected Coronary Microvascular and Vasomotor Dysfunction

An interventional study of Invasive coronary physiological measurements in Coronary Microvascular Dysfunction (CMD) and Vasospasm, Coronary, sponsored by Mid and South Essex NHS Foundation Trust. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Mid and South Essex NHS Foundation Trust · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn more about the diagnosis of coronary endothelium function and coronary vasospasm using a dedicated invasive protocol in patients who has angina without obstruction in their main heart arteries. The main question it aims to answer is the feasibility, reproducibility, and safety of this invasive protocol:

Does this invasive protocol diagnose coronary endothelial dysfunction and vasospasm without issues?

Participants already having invasive coronary angiogram and physiological studies will undergo additional physiological measurements during the same procedure.

Participants will enrol in a symptoms and quality of life questionnaire using dedicated questionnaires and a mobile application to assess the burden of their symptoms before and after the invasive procedure and up to 12 months follow up.

A subset of participants will undergo a repeat set of these measurements to assess reproducibility of the invasive protocol.

A subset of the participants will also undergo a cardiac MRI to assess correlation with the invasive protocol measurements.

02

Conditions studied

  • Coronary Microvascular Dysfunction (CMD)
  • Vasospasm, Coronary

Browse trials for

03

In context

Coronary Vasospasm

27 studies on the registry are indexed under Coronary Vasospasm; 7 are open to participants now.

This study's planned enrollment of 100 is close to the median of 95 across 14 interventional studies indexed under Coronary Vasospasm.

Browse Coronary Vasospasm studies →

Lead sponsor

Mid and South Essex NHS Foundation Trust is the lead sponsor of 34 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with symptoms suggestive of angina.
  2. Evidence of unobstructed coronary arteries on invasive or non-invasive coronary angiography (coronary stenosis \<50% and /or FFR >0.80).
  3. Above the age of 18.
  4. The subject has been informed of the nature of the study, agrees to its provisions and has signed written .

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy.
  2. to angiography and/or physiological assessment with adenosine or acetylcholine.
  3. Previous coronary artery bypass graft (CABG).
  4. Moderate to severe valvular heart disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Invasive Coronary function Assessment arm

    Invasive coronary endothelial function and vasospasm assessment

    Procedure: Invasive coronary physiological measurements

Interventions

  • ProcedureInvasive coronary physiological measurements

    Invasive assessment of changes in coronary blood flow, resistance, and distal pressure in response to acetylcholine infusion. These will be measured during a clinical indicated invasive coronary angiogram procedure and physiological studies using a standard coronary pressure wire and a dedicated infusion catheter.

06

What researchers measure

Primary outcomes

  1. Feasibility outcome

    Proportion of patients in whom the full invasive protocol (baseline and post-stimulation measurements) is successfully completed without major technical issues or protocol deviations.

    Time frame: At baseline

Secondary outcomes

  1. Reproducibility outcome

    Intra- and inter-operator variability of measurements quantified using intraclass correlation coefficients and Bland-Altman plots in a predefined reproducibility subset.

    Time frame: At baseline

  2. Safety outcome

    Incidence of adverse events related to the procedure or medications.

    Time frame: At Baseline and up to 12 months

  3. Correlation between invasive and non-invasive measures of endothelial-dependent coronary microvascular dysfunction.

    Strength of correlation (unit of measure = correlation coefficient, r) between invasive indices of endothelial-dependent coronary microvascular function obtained during the study protocol (absolute coronary blood flow and absolute microvascular resistance measured by continuous thermodilution during intracoronary acetylcholine testing) and non-invasive measures of myocardial perfusion (myocardial perfusion reserve obtained from cardiac stress perfusion imaging). Diagnostic agreement for identifying endothelial-dependent microvascular dysfunction will also be assessed (unit of measure = area under ROC curve, sensitivity, and specificity), using the invasive assessment as the reference standard.

    Time frame: From baseline and up to 3 months

  4. Correlation between invasive physiological indices of coronary microvascular function and symptom burden at baseline.

    The strength of correlation (Pearson or Spearman correlation coefficient; unit of measure = correlation coefficient, r) between invasive physiological measurements of coronary microvascular function obtained during the study protocol (e.g., absolute coronary blood flow and absolute microvascular resistance derived by continuous thermodilution during acetylcholine testing) and patient-reported symptom burden assessed at baseline using validated questionnaires (Seattle Angina Questionnaire-7 \[SAQ-7\] and EQ-5D-5L scores).

    Time frame: Baseline (at time of invasive coronary function testing).

  5. Change in symptoms, quality of life, and need for further investigation or treatment during follow-up.

    Change from baseline to follow-up in patient-reported symptoms and quality of life (unit of measure = change in questionnaire score) as assessed using the SAQ-7 and EQ-5D-5L questionnaires, and the proportion of patients (%) requiring additional cardiac investigations or treatment changes during follow-up.

    Time frame: From baseline to 12 months follow-up

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 13, 2026
StartEst.
Dec 15, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07337005
Lead sponsor
Mid and South Essex NHS Foundation Trust
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Dec 15, 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion